New hope for advanced cancers: experimental drug XNW28012 enters human trials
NCT ID NCT06799637
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called XNW28012 in people with advanced solid tumors (pancreatic, ovarian, cervical, or colorectal cancers) that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. About 350 participants will receive the drug every three weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- XNW28012
- What this could lead to
- If successful, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
- What could go wrong
- This is an early phase 1/2 trial with a small number of participants, so the drug may not prove effective or safe enough for wider use. Side effects are unknown and will be closely monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Cancer Hospital of Harbin Medical University
RECRUITINGHarbin, Heilongjiang, China
-
Affiliated Hospital of Binzhou Medical College
RECRUITINGBinzhou, Shandong, China
-
Affiliated Hospital of Guizhou Medical University
RECRUITINGGuiyang, Guizhou, China
-
Affiliated Hospital of Hebei University
RECRUITINGBaoding, Hebei, China
-
Beijing Friendship Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
-
Chongqing University Cancer Hospital
RECRUITINGChongqing, Chongqing Municipality, China
-
First Affiliated Hospital of Gannan Medical College
RECRUITINGGanzhou, Jiangxi, China
-
First Affiliated Hospital of Henan University of Science and Technology
RECRUITINGLuoyang, Henan, China
-
First Affiliated Hospital of Kunming Medical University
RECRUITINGYunnan, Kunming, China
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
-
Fujian Provincial Cancer Hospital
RECRUITINGFuzhou, Fujian, China
-
Hubei Cancer Hospital
RECRUITINGWuhan, Hubei, China
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, China
-
Jinan Central Hospital
RECRUITINGJinan, Shandong, China
-
Linyi Cancer Hospital
RECRUITINGLinyi, Shandong, China
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, China
-
Second Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, China
-
Sichuan Provincial People's Hospital
RECRUITINGChengdu, Sichuan, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, China
-
The First Affiliated Hospital of University of Science and Technology of China
RECRUITINGHefei, Anhui, China
-
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
-
The Second Xiangya Hospital Of Central South University
RECRUITINGChangsha, Hunan, China
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, China
-
Yunnan Cancer Hospital
RECRUITINGKunming, Yunnan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can your own immune cells beat advanced cancer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a new drug combo revive Immunotherapy's power against resistant tumors?